TY - JOUR
T1 - Treatment of benign prostatic hypertrophy with medrogestone
AU - Rangno, Robert E.
AU - McLeod, Peter J.
AU - Ruedy, John
AU - Ogilvie, R. I.
PY - 1971
Y1 - 1971
N2 - Twenty-four patients with established benign prostatic hypertrophy (BPH) were treated at random in a double-blind manner with one of two drug schedules: medrogestone for 24 weeks followed by placebo for 24 weeks, or the reverse order. Analysis of effects of treatment was made by assessment of frequency, nocturia, hesitancy, intermittency, force and size of urine stream, digital grading of prostate size, residual urine measured isotopically, cystoscopy with prostate needle biopsies, and cystogram. Medrogestone produced a significant reduction in the severity of BPH.
AB - Twenty-four patients with established benign prostatic hypertrophy (BPH) were treated at random in a double-blind manner with one of two drug schedules: medrogestone for 24 weeks followed by placebo for 24 weeks, or the reverse order. Analysis of effects of treatment was made by assessment of frequency, nocturia, hesitancy, intermittency, force and size of urine stream, digital grading of prostate size, residual urine measured isotopically, cystoscopy with prostate needle biopsies, and cystogram. Medrogestone produced a significant reduction in the severity of BPH.
UR - http://www.scopus.com/inward/record.url?scp=0015091041&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0015091041&partnerID=8YFLogxK
U2 - 10.1002/cpt1971124658
DO - 10.1002/cpt1971124658
M3 - Article
C2 - 4105445
AN - SCOPUS:0015091041
SN - 0009-9236
VL - 12
SP - 658
EP - 665
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
IS - 4
ER -